DT03 Rec'd PCT/PT0 1 3 JUL 2004

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV457868616U5
Express Mail Label Number

16. Other items or information: Application Data Sheet

July 13, 2009
Date of Deposit

Form PTO-1390-MOD U. S. Department of Commerce Patent and Trademark Office ATTORNEY'S DOCKET NUMBER (REV 10-96) PD/4-32249A U.S. APPLICATION NO. (If known, see 37 CFR 1.5) TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) 10/501445 CONCERNING A FILING UNDER 35 U.S.C. 371 INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED PCT/EP03/00973 31 January 2003 (31.01.03) 2 January 2002 (02.01.02) TITLE OF INVENTION PHENYLPYRIMIDINE AMINES AS IGE INHIBITORS APPLICANT(S) FOR DO/EO/US **BULUSU ET AL.** Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: 1. This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 2. 3. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4.  $\boxtimes$ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5.  $\bowtie$ A copy of the International Application as filed (35 U.S.C. 371(c)(2)) is transmitted herewith (required only if not transmitted by the International Bureau). has been transmitted by the International Bureau. (See Form PCT/IB/308) is not required, as the application was filed in the United States Receiving Office (RO/US). A translation of the International Application into English (35 U.S.C. 371(c)(2)). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C.371(c)(3)). are transmitted herewith (required only if not transmitted by the International Bureau). have been transmitted by the International Bureau. h. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). 8. An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)). 10. 🖂 A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11. to 16. below concern document(s) or information included. 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment. 14. A substitute specification. 15. A change of power of attorney and/or address letter.

| U.S. APPLICATION NO. (IPKnown,  | YU 5 01 4 4 5 INTERNATIONAL APPLICATION NO. PCT/EP03/00973 PD/4-32 |             |     |              |           |                 |     | DOCKET NUMBER  |                        |                |  |
|---|--|-------------|-----|--------------|-----------|-----------------|-----|----------------|------------------------|----------------|--|
| 17.   The following fe  | es are submi   | tted:       |     | <u>-</u>     |           |                 |     |                | CALCULATION            | S PTO USE ONLY |  |
| BASIC NATIONAL FEE (37 CFR 1.492(a) (1)-(5)):   |  |             |     |              |           |                 |     |                |                        |                |  |
| Search Report has been prepared by the EPO or JPO   |  |             |     |              |           |                 |     |                |                        |                |  |
| International preliminary examination fee paid to USPTO (37 CFR 1.482)\$730   |  |             |     |              |           |                 |     |                |                        |                |  |
| No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2))   |  |             |     |              |           |                 |     |                |                        |                |  |
| Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO  |  |             |     |              |           |                 |     |                |                        |                |  |
| International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)   |  |             |     |              |           |                 |     |                |                        |                |  |
| ENTER APPROPRIATE BASIC FEE AMOUNT =  |  |             |     |              |           |                 |     |                | \$ 920                 |                |  |
| Surcharge of \$130 for furnishing the oath of declaration later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(e)).  |  |             |     |              |           |                 |     |                | \$                     |                |  |
| CLAIMS  | NUMBE  | 1           | _   | NUMBER EXTRA | 1         |                 | ATE |                |                        |                |  |
| Total claims  | 9  | <del></del> | 0 = | 0            | X         | \$              | 18  |                | \$                     |                |  |
| Independent claims  | T CLAIM(S)   |             | 3 = | 0            | X +       | <u>\$</u><br>\$ | 86  |                | <u>\$</u>              |                |  |
| MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$ 290  TOTAL OF ABOVE CALCULATIONS =   |  |             |     |              |           |                 |     |                | \$ 920                 |                |  |
| Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be  |  |             |     |              |           |                 |     |                | Ψ 920                  |                |  |
| filed (Note 37 CFR 1.9, 1.27, 1.28).  |  |             |     |              |           |                 |     |                | \$                     |                |  |
| SUBTOTAL =  |  |             |     |              |           |                 |     |                | \$ 920                 |                |  |
| Processing fee of \$130 for furnishing the English translation later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(f)).   |  |             |     |              |           |                 |     |                | \$                     |                |  |
| TOTAL NATIONAL FEE =  |  |             |     |              |           |                 |     |                | \$ 920                 |                |  |
| Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40</b> per property +                              |  |             |     |              |           |                 |     |                | \$                     |                |  |
| TOTAL FEES ENCLOSED =   |  |             |     |              |           |                 |     |                | \$ 920                 |                |  |
|   |  |             |     |              |           |                 | -   |                | Amount to be: refunded | \$             |  |
|   |  |             |     |              |           |                 |     |                | charged                | \$             |  |
| a. A check in the   |  |             |     |              |           |                 |     |                |                        |                |  |
| b. Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$920 to cover the above fees. A duplicate copy of this form is enclosed.   |  |             |     |              |           |                 |     |                |                        |                |  |
| c.  The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.                          |  |             |     |              |           |                 |     |                |                        |                |  |
| NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status. |  |             |     |              |           |                 |     |                |                        |                |  |
| Send all correspondence to the address associated with Customer No. 001095, which is currently:   |  |             |     |              |           |                 |     |                |                        |                |  |
| Novartis Corporate Intellectual Property One Health Plaza, Building 430 Corporate Intellectual Property One Health Plaza, Building 430 Reg. No. 47,666  |  |             |     |              |           |                 |     | <del>0</del> ~ |                        |                |  |
| East Hanover, N   | J U7936-108  | U           |     | (86          | 52) 778-2 | 2614            |     |                |                        |                |  |